Diarrhea - instructions for use, doses, side effects, contraindications

Excipients: polymethylsiloxane, potato starch, lactose (sugar milk), sucrose (sugar), microcrystalline cellulose, colloidal silicon dioxide (aerosil), aspartame, povidone (Kollidon 90), xylitol (Xylitab 300), lactitol, kollidone SR, menthol, magnesium stearate, anise oil.

Description:Tablets are white or white with a yellowish tint of color, a flat-cylindrical shape with a risk, with the smell of anise. A slight "marble" is allowed.

Pharmacotherapeutic group:Antidiarrhoeic remedy

ATX: & nbsp

A.07.D.A Drugs that reduce the peristalsis of the digestive tract

A.07.D.A.03 Loperamide

Pharmacodynamics:

Loperamide, by binding to the opioid receptors of the intestinal wall (modulation of choline and adrenergic neurons through guanine nucleotides), reduces the tone and motility of smooth intestinal muscles (by inhibiting the release of acetylcholine and Pg). Slows down the peristalsis and increases the transit time of intestinal contents. Increases the tone of the anal sphincter, promotes retention of fecal masses and reduced urge to defecate.

The action comes quickly and lasts 4-6 hours.

Pharmacokinetics:

It is almost completely metabolized by the liver by conjugation.T1 / 2 (half-life) is 9-14 hours. It is excreted mainly with bile and kidneys (in the form of conjugated metabolites).

Indications:

Symptomatic treatment of acute and chronic diarrhea of various genesis (allergic, emotional, drug, radiation, with a change in diet and quality of food, in violation of metabolism and absorption, as an auxiliary for diarrhea of infectious genesis).

Regulation of stool in patients with ileostomy.

Contraindications:

Hypersensitivity to the drug, diverticulosis, intestinal obstruction, ulcerative colitis in the acute stage, diarrhea on the background of acute pseudomembranous enterocolitis, in the form of monotherapy - dysentery and other infections of the gastrointestinal tract; pregnancy (I trimester), lactation period, children's age (up to 6 years).

Carefully:Liver failure.

Dosing and Administration:

Inside, chewing, washing with water. Adults with acute and chronic diarrhea appointed in an initial dose of 2 tablets (4 mg); then - 1 tablet (2 mg) after each act of defecation (in the case of a loose stool); the maximum daily dose is 8 tablets (16 mg).

In acute diarrhea, children over 6 years of age are prescribed in an initial dose of 2 mg, then 2 mg after each act of defecation in the case of a loose stool; the maximum daily dose of 3 tablets (6 mg).

With the normalization of the stool or in the absence of stool for more than 12 hours, treatment with Diar should be discontinued.

Side effects:

Gastralgia, dry mouth, allergic reactions (skin rash), drowsiness, dizziness, intestinal colic, nausea, vomiting, constipation. Very rarely - intestinal obstruction.

Overdose:

Symptoms: depression of the central nervous system (CNS) (stupor, impaired coordination of movements, drowsiness, miosis, muscle hypertension, respiratory depression), intestinal obstruction.

Treatment: antidote - naloxone; Considering that the duration of action of loperamide is greater than that of naloxone, it is possible to re-introduce the latter. Symptomatic treatment: Activated carbon, gastric lavage, artificial ventilation (IVL). Medical surveillance is necessary for at least 48 hours.

Special instructions:

If there is no effect within 48 hours, the drug should be discontinued and consult a doctor.

Form release / dosage:

Tablets are chewable.

Packaging:

For 4, 6, 7 or 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

For 1, 2 or 3 contour squares with instructions for use are placed in a pack of cardboard.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

2 years. Do not use the expiration date printed on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LS-000845

Date of registration:27.07.2010

The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia

Manufacturer: & nbsp

OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia

Information update date: & nbsp22.10.2015

Illustrated instructions

Instructions

Dyara (Diara)